MedTrace Logo

MYLUNG Consortium Part 3: Observational Study

NCT05885698 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 7500

Last updated 2026-05-18

No results posted yet for this study

Summary

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • US Oncology Research

    lead INDUSTRY

Principal Investigators

  • Makenzi C. Evangelist, MD · New York Oncology Hematology

  • Patrick J. Ward, MD · Oncology Hematology Care Clinical Trials, LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05885698 on ClinicalTrials.gov